Wang Xuning, Wang Shixiang, Han Yalin, Xu Maolin, Li Peng, Ke Mu, Teng Zhipeng, Huang Pu, Diao Ziyan, Yan Yongfeng, Meng Qingyu, Kuang Yanshen, Zheng Wei, Liu Hongyi, Liu Xuesong, Jia Baoqing
The Air Force Hospital of Northern Theater PLA, Shenyang, People's Republic of China.
Department of General Surgery, The First Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
Int J Gen Med. 2021 Nov 16;14:8293-8299. doi: 10.2147/IJGM.S325910. eCollection 2021.
Immunotherapy is considered as a powerful and promising clinical approach for the treatment of gastric cancer (GC). However, it is still challenging to precisely screen patients who potentially benefit from immune checkpoint therapy (ICT). Identification of potential biomarkers for selecting patients sensitive to immunotherapy was urgently needed.
Public sequence data and corresponding clinical data were used to explore the potential biomarkers for immunotherapy.
We found that is the most frequently mutated gene and its mutation is highly correlated with prognosis in gastric cancer patients. Interestingly, patients with mutated CSMD1 exhibit a high mutation burden and upregulated PDL1 expression. The ratio of microsatellite instability (MSI) in the CSMD1 mutation cohort was higher than that in the cohort without CSMD1 mutation. Furthermore, patients with CSMD1 mutation have been found to possess a higher number of activated CD4+ T cells and neoantigens.
CSMD1 mutation may act as a novel biomarker for assessing the survival and immune therapy response in patients with gastric cancer.
免疫疗法被认为是治疗胃癌（GC）的一种强大且有前景的临床方法。然而，精确筛选可能从免疫检查点疗法（ICT）中获益的患者仍然具有挑战性。迫切需要鉴定用于选择对免疫疗法敏感患者的潜在生物标志物。
使用公开的序列数据和相应的临床数据来探索免疫疗法的潜在生物标志物。
我们发现 是胃癌患者中最常发生突变的基因，其突变与预后高度相关。有趣的是，CSMD1 突变的患者表现出高突变负荷和 PDL1 表达上调。CSMD1 突变队列中的微卫星不稳定性（MSI）比率高于无 CSMD1 突变的队列。此外，已发现 CSMD1 突变的患者拥有更多活化的 CD4+ T 细胞和新抗原。
CSMD1 突变可能作为评估胃癌患者生存和免疫治疗反应的一种新型生物标志物。
需注意，原文中“我们发现 是胃癌患者中最常发生突变的基因”这里缺失了具体基因名称，翻译时保留了原文格式。
